Patel Engineering share price surged by 6.1% to ₹48.50 on Thursday after the company announced third-quarter earnings for the period ending December 2024.

The company reported a consolidated net profit of ₹80.24 crore, marking a 14.49% year-on-year increase from ₹70.24 crores in the same period last year, signalling a solid financial performance.

Revenue Growth Reflects Strong Operational Execution

Patel Engineering’s revenue for the October-December quarter increased significantly, rising to ₹1,206 crore, up from ₹1,061 crore in the year-ago period. This growth underscores the company’s strong operational capabilities and successful execution of its strategic initiatives.

Expenses and Operational Costs

The company’s expenses for the quarter were reported at ₹1,125 crore, compared to ₹1,030.94 crore in the corresponding quarter of the previous fiscal year. Despite the increase in costs, Patel Engineering’s growth in both revenue and net profit reflects the positive impact of its operations.

About Patel Engineering

Founded in 1949, Patel Engineering has built a diverse portfolio that includes significant projects in sectors such as dams, tunnels, hydroelectric projects, irrigation, highways, roads, bridges, railways, and real estate.

The company has also expanded its expertise into the Engineering, Procurement, and Construction (EPC) sector and real estate development, having been involved in the construction of various structures, including hotels, theatres, sports stadiums, and office buildings.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

NTPC Green Energy announced on February 12 that its joint venture with ONGC, ONGC NTPC Green Private Ltd (ONGPL), has signed a share purchase agreement (SPA) to acquire a 100% stake in Ayana Renewable Power Private Ltd for an enterprise value of ₹19,500 crore ($2.3 billion).

The acquisition aims to boost ONGPL’s renewable energy portfolio and contribute to India’s transition to clean energy.

Details of the Acquisition

The acquisition involves the purchase of Ayana Renewable Power from its current stakeholders, including the National Investment and Infrastructure Fund (NIIF), BII South Asia Renewables Ltd, British International Investment Plc (BII), and Eversource Capital.

Ayana is one of India’s leading renewable energy companies, specialising in large-scale solar and wind power projects.

Strategic Move for Expanding Renewable Energy Portfolio

This acquisition marks a key milestone for ONGPL, being its first strategic move since the joint venture was established in November 2024. It accelerates ONGPL’s expansion into the renewable energy sector and underscores its commitment to sustainability.

The deal is in line with the broader goals of ONGC and NTPC, the parent companies of ONGPL, both of which aim to achieve net-zero emissions by 2038 and 2050, respectively.

Regulatory Approvals Pending

The completion of the transaction is subject to fulfilling conditions precedent and receiving the necessary regulatory approvals. Once finalised, the acquisition will significantly enhance ONGPL’s footprint in India’s growing renewable energy market.

Stock Performance 

On February 13, 2025, NTPC share price traded 0.34% higher at ₹307.30 at 11:37 AM (IST). NTPC’s share price reached a 52-week high of ₹448.30, and a 52-week low of ₹296.85. As per BSE, the total traded volume for the stock stood at 3.12 lakh shares with a turnover of ₹9.57 crore.

At the current price, NTPC shares are trading at a price-to-earnings (P/E) ratio of 15.33x, based on its trailing 12-month earnings per share (EPS) of ₹20.04, and a price-to-book (P/B) ratio of 1.91, according to exchange data.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Shares of Godrej Industries Ltd surged after the business conglomerate posted robust financial results for the December quarter of FY24.

The company reported a 76.9% year-on-year (YoY) jump in net profit, reaching ₹188.2 crore, compared to ₹106.4 crore in the same period last year. This strong performance was further complemented by a substantial increase in revenue and operating profitability.

Revenue and EBITDA Growth

Godrej Industries’ revenue from operations rose by 34.4% YoY to ₹4,824.8 crore for Q3FY24, up from ₹3,590 crore in Q3FY23. The company’s earnings before interest, tax, depreciation, and amortisation (EBITDA) increased by an impressive 113.75% YoY, reaching ₹596.8 crore compared to ₹279.2 crore last year.

This strong EBITDA growth was reflected in a significant rise in EBITDA margin, which climbed to 12.4% from 7.8% in the corresponding quarter of the previous year.

Segment-wise Performance

• Godrej Consumer: 

GCPL saw a 14% YoY decline in consolidated net profit (excluding exceptional items and one-offs), impacted by temporary headwinds. However, consolidated sales grew by 6%.

In the home care segment, revenue grew by 4%, despite seasonal weakness in household insecticides, which was offset by strong double-digit growth in air fresheners and fabric care.

The personal care segment saw a 2% increase, with personal wash volumes declining in the mid-to-high single digits, while hair colour volumes grew in the mid-single digits, particularly driven by double-digit growth in Godrej Expert Rich Crème access packs.

Chemicals Segment:

The chemicals segment showed robust performance, with Q3FY24 revenue up 44% and profit before interest and taxes (PBIT) surging 266%. Exports contributed 30% of total revenue, with Q3 exports rising 58% and 9M FY25 exports increasing 23%.

• Godrej Properties: 

Godrej Properties recorded ₹5,446 crore in booking value for Q3FY25, driven by 4.07 million square feet of sales. This marks the sixth consecutive quarter with bookings above ₹5,000 crore.

The company added four new projects with a total saleable area of 5.9 million square feet, translating to an estimated booking value of ₹10,800 crore. It delivered 2.6 million square feet of projects in Q3, bringing the year-to-date total to 11.9 million square feet. Additionally, Godrej Properties raised ₹6,000 crore through India’s largest QIP by a real estate company.

• Godrej Agrovet: 

Godrej Agrovet posted a 45% YoY increase in EBIT per tonne, reaching ₹1,935, up from ₹1,338 in Q3FY24, driven by favourable commodity positions. The vegetable oil segment saw a 72% rise in results, benefiting from higher realisations in crude palm oil and palm kernel oil, along with improved oil extraction ratios.

The crop protection business experienced a decline in revenue, posting ₹193 crore compared to ₹222 crore in Q3FY23. The dairy segment saw flat revenue and margins YoY, due to stable volumes and voluntary controls.

Stock Performance 

On February 13, 2025, Godrej Industries share price traded 8.06% higher at ₹878.40 at 11:09 AM (IST). Godrej Industries’s share price reached a 52-week high of ₹1,313.95 on September 06, 2024, and a 52-week low of ₹724.35 on June 04, 2025. As per BSE, the total traded volume for the stock stood at 0.34 lakh shares with a turnover of ₹2.95 crore.

At the current price, Godrej Industries shares are trading at a price-to-earnings (P/E) ratio of 285.19x, based on its trailing 12-month earnings per share (EPS) of ₹3.08, and a price-to-book (P/B) ratio of 16.66, according to exchange data.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

 

ITD Cementation India Ltd, a leading engineering and construction firm, reported a year-on-year (YoY) increase in its net profit for the third quarter of FY25, reaching ₹87 crore compared to ₹78.4 crore in the same period last year. The company’s strong performance reflects steady growth across various metrics despite a slight contraction in its EBITDA margin.

Revenue and Profit Show Solid Growth

The company’s revenue from operations rose YoY, reaching ₹2,244.9 crore for Q3FY25, up from ₹2,017.2 crore in the corresponding quarter of FY24. The growth in both revenue and net profit highlights ITD Cementation’s continued strength in the competitive construction sector.

EBITDA Growth Slows but Remains Positive

At the operating level, ITD Cementation’s earnings before interest, tax, depreciation, and amortization (EBITDA) rose by a modest YoY to ₹206.1 crore, compared to ₹204.8 crore in Q3FY24. Despite the increase in EBITDA, the company’s EBITDA margin shrank to 9.2% from 10.2% in the previous year, indicating slightly reduced operational efficiency.

9 Month Performance

For the first nine months of FY25, ITD Cementation reported a significant YoY increase in total operating income, reaching ₹6,617 crore. EBITDA for the period stood at ₹655 crore, up YoY, while profit after tax (PAT) surged to ₹259 crore, demonstrating robust financial performance over the nine months.

Robust Order Book and Conservative Financing

As of December 31, 2024, the company’s consolidated order book stood at ₹19,893 crore, with new orders worth approximately ₹6,370 crore secured in FY25 to date. ITD Cementation continues to maintain a conservative financial stance, with a net debt-to-equity ratio of 0.43x, ensuring a strong and stable financial position moving forward.

Stock Performance

On February 13, 2025, ITD Cementation share price traded 0.88% lower at ₹526.35 at 10:07 AM (IST). ITD Cementation’s share price reached a 52-week high of ₹694.45 on October 04, 2024, and a 52-week low of ₹256.40 on March 13, 2025. As per BSE, the total traded volume for the stock stood at 5428 shares with a turnover of ₹28.64 lakhs.

At the current price, ITD Cementation shares are trading at a price-to-earnings (P/E) ratio of 26.59x, based on its trailing 12-month earnings per share (EPS) of ₹19.80, and a price-to-book (P/B) ratio of 5.54, according to exchange data.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

PTC India Limited has announced a remarkable 58.2% year-on-year (YoY) increase in its net profit for the October-December quarter of FY25, reaching ₹176.4 crore, compared to ₹111.5 crore in the same period last year. This performance highlights the company’s resilience despite minimal change in revenue.

PTC India’s Q3FY25 Performance 

The company’s revenue for the quarter remained almost unchanged at ₹3,420.8 crore, reflecting a slight dip from ₹3,428 crore in Q3FY24. This stability in revenue underscores PTC India’s ability to maintain operational efficiency while increasing profitability.

EBITDA Growth and Improved Margins

PTC India’s operating performance also showed significant improvement, with earnings before interest, tax, depreciation, and amortisation (EBITDA) rising by 24% YoY to ₹309.6 crore, up from ₹249.7 crore in Q3FY24. The EBITDA margin saw a notable increase to 9.1%, up from 7.3% in the previous year, driven by better operational efficiencies.

Continued Leadership in India’s Energy Sector

As a leading power trader in India, PTC India plays a critical role in the country’s energy sector. The company also operates through its subsidiaries, including PTC India Financial Services and PTC Energy, further strengthening its position in the industry.

Stock Performance

On February 13, 2025, PTC India share price traded 3.01% higher at ₹136.95.23 at 9:45 AM (IST). PTC India’s share price reached a 52-week high of ₹246.55 on September 16, 2024, and a 52-week low of ₹127.75 on January 13, 2025. As per BSE, the total traded volume for the stock stood at 0.52 lakh shares with a turnover of ₹71.56 lakhs.

At the current price, PTC India shares are trading at a price-to-earnings (P/E) ratio of 9.74x, based on its trailing 12-month earnings per share (EPS) of ₹14.06, and a price-to-book (P/B) ratio of 0.98, according to exchange data.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Suven Pharmaceuticals Ltd announced a significant 77.1% year-on-year (YoY) increase in net profit for the third quarter of FY25, reporting ₹82.9 crore compared to ₹46.8 crore in the same period last year. Revenue from operations also saw a strong rise, jumping 39.8% YoY to ₹307.2 crore from ₹219.8 crore in Q3FY24.

EBITDA and Margins See Strong Growth

At the operating level, Suven Pharma’s EBITDA (earnings before interest, tax, depreciation, and amortisation) soared by 78.2% YoY to ₹117.8 crore from ₹66 crore. The EBITDA margin improved significantly, expanding to 38.4% from 30.1% in the year-ago period. The company’s gross margins for the quarter stood at 71.5%, while adjusted EBITDA margins came in at 38.7%.

Pharma CDMO Segment Fuels Growth

The primary driver of Suven Pharma’s Q3FY25 performance was the pharma contract development and manufacturing organisation (CDMO) segment, which recorded a remarkable 101% YoY growth. This surge was supported by the company’s continued research and development (R&D) investments and business development initiatives.

In the pharma CDMO segment, the company also witnessed a twofold YoY increase in requests for quotations (RFQs) for the first nine months of FY25, reflecting sustained demand across different stages, driven by favourable macroeconomic trends.

Expansion in Drug Development Pipeline

During the quarter, Suven Pharma added two new molecules to its pipeline—one progressing to phase 3 and another being directly included in phase 3 as a lateral addition. This brings the total number of active phase 3 projects to 15, covering nine different molecules.

Capital Expenditure and Financial Position

For the first nine months of FY25, Suven Pharma incurred a capital expenditure of ₹938 million. The company also generated ₹1.33 billion in free cash flow, further strengthening its financial position. As of the end of Q3FY25, it maintained a cash and bank balance of ₹2.82 billion.

Stocks Performance

On February 13, 2025, Suven Pharmaceuticals share price traded 4.26% higher at ₹1,090.23 at 9:18 AM (IST). Suven Pharmaceuticals’s share price reached a 52-week high of ₹1,359 on December 2, 2024, and a 52-week low of ₹597 on June 04, 2024. As per BSE, the total traded volume for the stock stood at 349 shares with a turnover of ₹3.79 lakhs.

At the current price, Suven Pharmaceuticals shares are trading at a price-to-earnings (P/E) ratio of 119.46x, based on its trailing 12-month earnings per share (EPS) of ₹9.71, and a price-to-book (P/B) ratio of 13.39, according to exchange data.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

The Reserve Bank of India (RBI) on Wednesday announced the lifting of supervisory restrictions previously imposed on Kotak Mahindra Bank, allowing the bank to resume onboarding new customers through its online channels and issue new credit cards. The restrictions had been in place since April 24, 2024, under Section 35A of the Banking Regulation Act, 1949.

Reason Behind the Restrictions

The RBI had imposed these restrictions following its IT Examination of the bank for the years 2022 and 2023. The central bank cited significant concerns and the continued failure of Kotak Mahindra Bank to address these issues in a comprehensive and timely manner. The restrictions prohibited the bank from onboarding new customers through online and mobile banking channels and from issuing new credit cards, though existing customers continued to receive services.

In its April 2024 release, the RBI highlighted serious deficiencies and non-compliances in several critical areas, including IT inventory management, patch and change management, user access management, vendor risk management, data security and data leak prevention strategy, business continuity, and disaster recovery rigour and drill.

Bank’s Corrective Measures and RBI’s Review

Following the imposition of restrictions, Kotak Mahindra Bank initiated remedial measures to address the RBI’s supervisory concerns. The bank also conducted an external audit with prior approval from the RBI to validate compliance with regulatory requirements.

In its latest statement, the RBI confirmed that it was satisfied with the corrective measures undertaken by the bank. “Subsequently, the bank initiated remedial measures to address the supervisory concerns and submitted compliances to the Reserve Bank. The bank also commissioned an external audit, with prior approval of RBI, to validate the compliances. Now, having satisfied itself based on the submissions and remedial measures undertaken by the bank, the Reserve Bank has decided to lift the aforementioned restrictions placed on Kotak Mahindra Bank Limited,” the central bank stated.

Kotak Mahindra Bank Resumes Full Operations

With the lifting of restrictions, Kotak Mahindra Bank can now fully resume its operations, including onboarding new customers through digital channels and issuing new credit cards. The development marks a significant step for the bank in restoring normal business activities after addressing regulatory concerns.

The RBI’s decision reflects confidence in the remedial measures implemented by the bank, ensuring better compliance with IT and cybersecurity frameworks in the future. Kotak Mahindra Bank is now expected to strengthen its internal IT governance and risk management processes to prevent similar issues going forward.

Stock Performance 

On February 13, 2025, Kotak Mahindra Bank share price ended 1.35% higher at ₹1,943.30. Kotak Mahindra Bank’s share price reached a 52-week high of ₹1,969.90 on February 11, 2025, and a 52-week low of ₹1,544.15 on May 03, 2024. As per BSE, the total traded volume for the stock stood at 0.49 lakh shares with a turnover of ₹9.57 crore.

At the current price, Kotak Mahindra Bank shares are trading at a price-to-earnings (P/E) ratio of 22.69x, based on its trailing 12-month earnings per share (EPS) of ₹85.66, and a price-to-book (P/B) ratio of 3.49, according to exchange data.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

The Nifty 50 index witnessed a modest recovery ahead of its weekly expiry, showing a gradual upside on Wednesday, February 14, 2025. The index traded within a range-bound manner, oscillating between 22,800 and 23,071 levels. Despite the constrained movement, the Nifty 50 closed above the key 23,000 mark, ending the day with a minor fall of 27 points at 23,046.

Stocks Under F&O Ban on Nifty’s Weekly Expiry Day

As the Nifty weekly expiry approaches on Thursday, February 13, 2025, the National Stock Exchange (NSE) has imposed a trading ban on 1 stock in the futures and options (F&O) segment. The ban was triggered as these securities breached 95% of the market-wide position limit (MWPL). While trading in F&O for these stocks is restricted, they remain available for trading in the cash market.

The stocks under the F&O ban for February 13 include:

• Manappuram Finance

On February 12, 2025, Manappuram Finance’ share price fell 2.89%, closing at ₹191.70. According to BSE data, the stock recorded a total traded volume of 7.54 lakh shares, translating to a turnover of ₹14.44 crore.

At the current price, Manappuram Finance shares are trading at a price-to-earnings (P/E) ratio of 9.15x, based on its trailing 12-month earnings per share (EPS) of ₹20.94, and a price-to-book (P/B) ratio of 1.46, according to exchange data.

Why Are Stocks Under F&O Ban?

According to an NSE statement from the NSE, “Derivative contracts in these securities have crossed 95% of the market-wide position limit and are placed under the stock exchange’s ban period. All clients/members shall trade in the derivative contracts of said securities only to decrease their positions through offsetting trades. Any increase in open positions will attract penal and disciplinary action.”

When stocks are placed under the F&O ban period, no new positions can be initiated in their derivative contracts.

Key Stock’s Results on Nifty Weekly Expiry Day

The Thursday trading session will be significant for traders as it marks the weekly expiry of Nifty 50 options contracts. Additionally, several companies, including Hindalco Industries, Ipca Laboratories, Afcons Infrastructure, Allcargo Logistics, Ansal Housing, Concord Biotech, Deepak Nitrite, Godfrey Phillips, HealthCare Global Enterprises, Indo Farm Equipment, Manappuram Finance, Radiant Cash Management Services, R Systems International, Senco Gold, SJVN, Texmo Pipes & Products, and United Breweries, are set to announce their quarterly earnings on February 13.

About Nifty Weekly Expiry Day?

Nifty weekly contracts expire every Thursday unless it falls on a trading holiday, in which case the expiry shifts to the previous trading day. All contracts are settled at the normal market closing time on the expiry day or at a later time as determined by the exchange.

Additionally, if the last Thursday of the expiry period is a trading holiday, the expiry for individual securities is moved to the preceding trading session. Notably, in MarketWatch, expiry dates are not displayed for the last week’s contracts, as they are considered monthly contracts. Instead, only the month’s name and the strike price are shown.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

On February 10, 2025, Bikaji Foods share price traded 2.67% lower at ₹641.95 at 12:09 PM (IST). Bikaji Foods’s share price reached a 52-week high of ₹1,005.00 on September 27, 2024, and a 52-week low of ₹475.50 on March 15, 2024. As per BSE, the total traded volume for the stock stood at 0.31 lakh shares with a turnover of ₹1.99 crore.

At the current price, Bikaji Foods shares are trading at a price-to-earnings (P/E) ratio of 57.51x, based on its trailing 12-month earnings per share (EPS) of ₹11.16, and a price-to-book (P/B) ratio of 12.02, according to exchange data.

Shareholding Details

As of December 31, 2024, Bikaji Foods promoters held 74.98% of the shares, Foreign Institutional Investors (FIIs) owned 7.70%, and Domestic Institutional Investors (DIIs) held 11.96%.

Bikaji Foods Ltd Q3 FY25 Results

Bikaji Foods reported a 39% year-on-year (YoY) decline in net profit for Q3FY25, posting ₹28.6 crore, down from ₹46.6 crore in the same quarter last year.

The drop in profit was mainly due to weaker operational performance, despite a moderate 14.5% YoY growth in revenue, which reached ₹714.9 crore, supported by a 3% rise in volumes.

Earnings before interest, taxes, depreciation, and amortisation (EBITDA) fell 26% YoY to ₹55.5 crore, while the EBITDA margin contracted sharply by 425 basis points to 7.8%, primarily due to inflationary pressures and higher raw material costs.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.